Skip to main content

Table 1 Definition of the 5 candidate biomarker signatures and estimated prevalences with included biomarker subgroup combinations, in the order AR, DRD, TP53, and TEfus (where “+” indicates mutated, “−” wild-type/non-mutated)

From: The ProBio trial: molecular biomarkers for advancing personalized treatment decision in patients with metastatic castration-resistant prostate cancer

TP53 and ARxx  xx         0.5
TP53+  xx  xx  xx  x0.37
DRD+    xxxx    xxx0.19
TEfus+ x x x x x x x 0.32